Single Dose Cefepime Versus Cefuroxime Plus Metronidazole as a Prophylactic Antibiotic During Emergency Intrapartum Cesarean Section


Compare between cefepime versus routine antibiotics as a prophylactic antibiotic during emergency cesarean section in a tertiary center of obstetric care

Full Title of Study: “Single Dose Cefepime Versus Cefuroxime Plus Metronidazole as a Prophylactic Antibiotic: A Randomized Controlled Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: February 1, 2020

Detailed Description

This is a randomized double blinded study which compare between single dose cefepime versus cefuroxime plus metronidazole during emergency intrapartum cesarean section.

Outcomes will include fever, wound infection, and urinary tract infection.


  • Drug: Cefepime
    • Antibiotic prophylaxis
  • Drug: Cefuroxime plus Metronidazole
    • Antibiotic prophylaxis

Arms, Groups and Cohorts

  • Active Comparator: “Cefepime” , “Maxipime®” 1 gm
    • Patient will receive “Cefepime” ,”Maxipime®” 1 gm IV during cesarean section just before skin incision
  • Active Comparator: “Cefuroxime”, “Zinnat®” 1gm plus “metronidazole”Flagyl®” 500
    • Patient will receive “Cefuroxime”, “Zinnat®” 1gm ,and “metronidazole”Flagyl®” 500 IV; just before skin incision for emergency cesarean section

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of surgical site wound infection
    • Time Frame: one week
    • Examining the wound after one week of the surgery to detect any infection

Participating in This Clinical Trial

Inclusion Criteria

  • intrapartum caesarean section

Exclusion Criteria

  • evidence of infection

Gender Eligibility: Female

Minimum Age: 20 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Assiut University
  • Collaborator
    • Yasser Esmat Mohammed
  • Provider of Information About this Clinical Study
    • Principal Investigator: Osama Saber Thabet Abdalmageed, Consultant of Obstetrics and gynecology – Assiut University
  • Overall Contact(s)
    • Abdalmageed Abdalmageed, +201007972027,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.